Clinical Study of Transurethral Prostate Cancer Plasma Resection Treatment on Urinary Retention and Micturition in Advanced Prostate Cancer
Objective:To observe the effect of transurethral plasma resection of Prostate Cancer(TuPkR-PCa)on the improvement of urination symptoms in patients with advanced prostate cancer with urinary retention(APCa-UR).Methods:A retrospective study was performed on 51 patients with APCa-UR admitted in Suqian Zhongwu Hospital and Xuzhou Central Hospital from June 2016 to May 2020.Patients were divided into two groups according to different treatment methods.Non-surgical group(34 patients):indwelling urinary catheter,simultaneous abiraterone acetate and goserelin endocrine therapy,to try to remove the catheter every 4 weeks.If it is not possible to urinate or residual urine was greater than 70 mL,the catheter was placed again.Surgical group(17 patients):TuPkR-PCa was performed to remove the transitional band prostate tissue,the urinary catheter was removed 1 week after the operation,and supplemented with abiraterone and goserelin endocrine therapy.Oncological index,IPSS and urinating condition of two groups before and after operation were compared.Results:There was no significant difference in baseline data between groups(χ2=0.362,0.012,0;P>0.05).IPSS score,PSA and prostate volume between the two groups 1 week before treatment,with no statistically significant difference(t=-0.120,0.870,-0.510,-0.620;P>0.05).3 months after treatment,TuPkR-PCa was more effective than endocrine therapy in improving APCa-UR symptoms,with statistically significant difference(t=9.070,P<0.05).Conclusion:In the treatment of APCa-UR patients,TuPkR-PCa can effectively improve the quality of life without changing the oncological characteristics.
Advanced prostate cancerUrinary retentionTransurethral resection of prostate cancerEfficacyOncological index